Indication
Hepatitis D
22 clinical trials
27 products
1 drug
Product
BulevirtideClinical trial
A Phase 1 Open-Label, Parallel-Design, Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide in Participants With Normal and Impaired Renal FunctionStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase 1, Open-label, Parallel-group, Multiple-dose Study to Evaluate the Pharmacokinetics of Bulevirtide in Participants With Normal and Impaired Hepatic FunctionStatus: Recruiting, Estimated PCD: 2025-02-01
Product
lonafarnibProduct
Peginterferon alfa-2aProduct
ritonavirClinical trial
An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With and Without Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-1)Status: Completed, Estimated PCD: 2015-09-01
Product
AB-729Clinical trial
A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis DeltaStatus: Active (not recruiting), Estimated PCD: 2020-11-26
Clinical trial
A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis DeltaStatus: Completed, Estimated PCD: 2022-04-05
Product
Peginterferon Lambda-1aClinical trial
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)Status: Active (not recruiting), Estimated PCD: 2024-06-15
Clinical trial
A Phase 2A Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose Ranging Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus CoinfectionStatus: Terminated, Estimated PCD: 2022-09-01
Product
ATI-2173Product
Peginterferon Alfa-2aProduct
Pegylated interferon-alfa-2aProduct
VireadProduct
REP 2139-MgClinical trial
Compassionate Use Access to REP 2139-Mg for the Treatment of Chronic HBV Infection or Chronic HBV / HDV Co-infectionStatus:
Product
Pegylated interferon alpha2aClinical trial
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)Status: Completed, Estimated PCD: 2022-10-06
Product
PEG IFN-alfa-2aProduct
RitonavirProduct
LonafarnibProduct
Peginterferon Lambda-1AClinical trial
A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)Status: Completed, Estimated PCD: 2018-07-20
Clinical trial
Double-blinded, Placebo-controlled, Munticenter, Phase IIa Clinical Trial of Hepalatide in Patients With Chronic Hepatitis DStatus: Completed, Estimated PCD: 2024-01-30
Product
HepalatideClinical trial
Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy: a Multicenter Prospective Real Life Data StudyStatus: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort StudyStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Product
Anti-HIV AgentsClinical trial
Hellenic Multicenter Real-life Clinical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLVStatus: Recruiting, Estimated PCD: 2023-11-30
Clinical trial
A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)Status: Recruiting, Estimated PCD: 2029-08-01
Product
VIR-2218Product
VIR-3434Product
NRTIClinical trial
Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Efficacy and Safety of Bulevirtide (BLV) Therapy in HDV Chronic Hepatitis (CHD) Patients in Italy: a National Real Life Data StudyStatus: Completed, Estimated PCD: 2023-04-30
Clinical trial
Open Label Phase 2 Clinical Study of Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta HepatitisStatus: Withdrawn, Estimated PCD: 2024-05-22
Product
Peginterferon LambdaClinical trial
Once Daily (QD) Dosing of Lonafarnib (LNF) Co-administered With Ritonavir (RTV) for Treatment of Chronic Hepatitis D Virus InfectionStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D InfectionStatus: Recruiting, Estimated PCD: 2027-11-01
Clinical trial
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis (SAVE-D Study)Status: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled Study With Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D VirusStatus: Active (not recruiting), Estimated PCD: 2023-10-19
Product
JNJ-73763989Drug
VarlilumabProduct
EntecavirProduct
Tenofovir disoproxilProduct
Tenofovir alafenamide